462 related articles for article (PubMed ID: 25779662)
1. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
[TBL] [Abstract][Full Text] [Related]
4. High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia.
Fu L; Fu H; Tian L; Xu K; Hu K; Wang J; Wang J; Jing H; Shi J; Ke X
Oncotarget; 2016 Mar; 7(13):15828-39. PubMed ID: 26910834
[TBL] [Abstract][Full Text] [Related]
5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
6. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
7. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
8. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Sun SM; Rockova V; Bullinger L; Dijkstra MK; Döhner H; Löwenberg B; Jongen-Lavrencic M
Leukemia; 2013 Jan; 27(1):100-6. PubMed ID: 22692398
[TBL] [Abstract][Full Text] [Related]
9. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
Shi J; Fu H; Jia Z; He K; Fu L; Wang W
EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
11. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
13. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
14. High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.
Fu L; Fu H; Zhou L; Xu K; Pang Y; Hu K; Wang J; Tian L; Liu Y; Wang J; Jing H; Huang W; Ke X; Shi J
Sci Rep; 2016 Sep; 6():34546. PubMed ID: 27686215
[TBL] [Abstract][Full Text] [Related]
15. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
[TBL] [Abstract][Full Text] [Related]
16. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
17. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
18. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
19. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
[TBL] [Abstract][Full Text] [Related]
20. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]